What Institut Curie does

Institut Curie is a French non-profit foundation recognized as serving public utility (fondation reconnue d'utilité publique), operating as France's leading cancer research and treatment center. It runs an integrated three-pillar model combining patient care, research, and education. The hospital ensemble comprises three sites — Hôpital de Paris (26 rue d'Ulm), Hôpital de Saint-Cloud, and the Centre de Protonthérapie d'Orsay — delivering the full spectrum of oncology treatments including chemotherapy, surgery, radiotherapy, proton therapy, immunotherapy, interventional radiology, hormonotherapy, and targeted therapies, alongside clinical trials. The Research Center operates 86 multidisciplinary teams producing 500+ publications per year across 78+ nationalities, supported by shared technological platforms and a dedicated Health Data Warehouse (entrepôt de données de santé).

The institution is funded through a combination of French national health insurance reimbursement for clinical services, public research grants, philanthropy, and revenue from international patients (~400 per year) and professional training. It monetizes its research output through a Technology Transfer Office that supports startup creation and licensing, and operates an international training network (My Curie College) that trains 1,000+ healthcare professionals annually. Strategic partnerships include EU-Life, Core For Life, OECI, NCI-NIH, Institut Weizmann, Université PSL, and INSERM (the latter two co-hosting the IHU Institut des Cancers des Femmes).

Institut Curie traces its origin to the Institut du Radium founded in 1909 and the Fondation Curie established in 1921 under Marie Curie's direct involvement, and it continues to leverage that heritage as a brand and fundraising asset. Day-to-day operations are governed by a management board led by Professor Alain Puisieux as Président du Directoire, with no parent company and no private-equity ownership.

Name

Institut Curie

Legal name

Institut Curie, fondation reconnue d'utilité publique

Website

https://curie.fr

Company type

Private

Founded year

1909

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Institut Curie is a French public-utility foundation operating France's leading cancer research and treatment center, combining three hospitals (including a proton therapy center), 86 research teams, and professional training programs to deliver oncology care, clinical trials, and translational research.

Ownership category

akta.pro rank

Product category

Oncology Treatment & Research

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

Keywords

• Cancer treatment services
• Clinical oncology research
• Radiation therapy services
• Proton therapy treatment
• Medical research foundation

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Healthcare Services Revenue: Institut Curie operates as a public hospital foundation recognized as serving public utility, providing cancer treatment services through its hospitals in Paris, Saint-Cloud, and Orsay. Revenue comes from healthcare reimbursement systems and public funding.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Institut Curie operates as France's leading cancer research and treatment center, providing comprehensive oncology services (chemotherapy, surgery, radiotherapy, proton therapy, immunotherapy, interventional radiology, hormonotherapy, and targeted therapies) across three hospital sites. It runs a multidisciplinary Research Center with 86 teams producing 500+ scientific publications annually, conducts clinical trials, and delivers education and training programs for healthcare professionals domestically and internationally.

Product overview

Institut Curie is a foundation recognized as being of public utility, serving as France's leading cancer research and treatment center. The organization operates three integrated pillars: (1) Patient Care through its hospital ensemble comprising the Hôpital de Paris, Hôpital de Saint-Cloud, and the proton therapy center in Orsay; (2) a Research Center with 86 multidisciplinary teams conducting fundamental and clinical research across three sites; and (3) Education and Training through various programs. Treatment services span multiple modalities including chemotherapy, surgery, radiotherapy, proton therapy, immunotherapy, interventional radiology, hormonotherapy, and targeted therapies. The institution also operates technology transfer services supporting startup creation and innovation commercialization, an IHU (Institut des Cancers des Femmes) focused on women's cancers, and maintains a museum dedicated to Marie Curie's scientific legacy.

Differentiator

Problem solved

Functional benefit

Brands

• My Curie College: An educational organism providing training for healthcare professionals.
• IHU Institut des Cancers des Femmes

Products and services

• Chemotherapy (Chimiothérapie) Cancer treatment using cytotoxic drugs to destroy cancer cells, offered as part of Institut Curie's comprehensive oncology services for patients with various cancer types.
• Surgery (Chirurgie) Surgical procedures for tumor removal and cancer treatment performed by specialized surgical oncologists at Institut Curie.
• Radiotherapy (Radiothérapie) Radiation therapy treatment using ionizing radiation to target and destroy cancer cells, part of Institut Curie's multidisciplinary cancer care.
• Proton Therapy (Protonthérapie) Advanced radiation therapy using proton beams available at the Centre de protonthérapie d'Orsay, offering precise tumor targeting with reduced side effects compared to conventional radiotherapy.
• Immunotherapy (Immunothérapie) Cancer treatment that harnesses the patient's immune system to fight cancer cells, offered at Institut Curie as part of innovative therapeutic approaches.
• Interventional Radiology (Radiologie interventionnelle) Minimally invasive image-guided procedures for cancer diagnosis and treatment performed at Institut Curie.
• Hormonotherapy (Hormonothérapie) Treatment that uses hormones to slow or stop the growth of certain cancers that respond to hormonal manipulation, offered for hormone-sensitive cancers.
• Targeted Therapies (Thérapies ciblées) Personalized cancer treatments that target specific genes, proteins, or tissue environments that contribute to cancer growth, representing precision medicine approaches in oncology.
• Clinical Trials (Essais cliniques) Clinical research programs offering patients access to innovative treatments and therapies through ongoing clinical trials conducted at Institut Curie.
• Cancer Research Center (Centre de Recherche) Multidisciplinary cancer research center with 86 research teams working across three sites (Paris, Saint-Cloud, Orsay) to advance scientific knowledge and translate discoveries into clinical applications.
• My Curie College - Professional Training Professional training organization for healthcare professionals, offering structured educational programs, international courses, medical and paramedical courses, and continuous education.
• Technology Transfer (Transfert de technologies) Technology transfer office supporting startup creation, licensing, and commercialization of research innovations from Institut Curie to industry partners.
• International Patients Office Dedicated service for international patients providing personalized care and follow-up with bilingual online monitoring platform and interpretation services, welcoming approximately 400 international patients annually.
• Institut des Cancers des Femmes (IHU) International research institute focused on women's cancers, created jointly by Institut Curie, Université PSL, and INSERM as a specialized research entity.

Quantifiable outcome

• 400 international patients treated annually with personalized care pathways
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and flagship.

• EU-LifecoreStrategic or Co-development PartnerNetwork stimulating excellence in life sciences in Europe by mobilizing 17 European research institutes for collaborative research and knowledge sharing in life sciences.
• Core For LifecoreStrategic or Co-development PartnerAlliance of 8 European life science technology platforms enabling shared access to advanced research technologies and methodologies across member institutions.
• NCI-NIH (National Cancer Institute)flagshipStrategic or Co-development PartnerPartnership with the National Cancer Institute at Bethesda, USA for collaborative research projects with associated funding and team exchanges.
• Institut WeizmannflagshipStrategic or Co-development PartnerPartnership with Institut Weizmann in Rehovot, Israel for collaborative research with associated funding and scientific exchanges.
• Université PSLflagshipStrategic or Co-development PartnerPartnership with Université Paris Sciences et Lettres for academic collaboration and the creation of the Institut des Cancers des Femmes (IHU).
• INSERMflagshipStrategic or Co-development PartnerPartnership with INSERM (Institut national de la santé et de la recherche médicale) for the creation of the Institut des Cancers des Femmes (IHU).
• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerOECI certification and label indicating Institut Curie meets European standards for comprehensive cancer care and research excellence.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Memorial Sloan Kettering Cancer Center: US-based specialty cancer hospital and research institute with a similar integrated research-and-care model, large clinical trials portfolio, and international patient program. Comparable in mission, though structured as a US nonprofit.
• Dana-Farber Cancer Institute: US-based Harvard-affiliated cancer research and treatment center with deep translational research, clinical trials, and international patient reach. Comparable as an NCI-tier academic oncology powerhouse.
• Gustave Roussy Institute: France's other flagship comprehensive cancer center, also OECI-accredited, combining research, proton/hadron therapy, and multi-site hospital care. Directly comparable in mission, scale, and French public-hospital funding model to Institut Curie.
• MD Anderson Cancer Center: US-based comprehensive cancer center globally recognized as #1 in oncology, integrating research, multidisciplinary care, and proton therapy. Closest global analogue to Institut Curie in mission and integrated research-care model.
• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center integrating research and clinical care, OECI-accredited, with international recognition in radiotherapy and translational oncology. Closest Benelux peer to Institut Curie's research-care-teaching model.
• German Cancer Research Center (DKFZ): Germany's leading national cancer research institute, partnered with Heidelberg University Hospital and a key EU-Life/Core For Life member alongside Institut Curie. Comparable in translational cancer research scale and EU grant capture.
• Royal Marsden Hospital: UK-based specialist cancer hospital with embedded research (Institute of Cancer Research), treating private and NHS international patients. Comparable as an OECI-tier European comprehensive cancer center with strong proton/precision radiotherapy capability.

Broad incumbents

• Karolinska Institutet / Karolinska University Hospital: Sweden's premier medical university and affiliated hospital, EU-Life member, with significant oncology research and proton therapy. Comparable as a European academic medical center with embedded cancer research infrastructure.
• Charité - Universitätsmedizin Berlin: Germany's largest university hospital and an EU-Life member, providing oncology among many other specialties. Comparable as a large European academic medical center with embedded research, though broader than a pure-play cancer institute.

Others

• European Organisation for Research and Treatment of Cancer (EORTC): Pan-European clinical trials network for cancer, partnering with institutions like Institut Curie to run multi-center oncology trials. Adjacent enabler rather than a competitor — comparable because trial participation is a core pillar of Curie's research-care model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/institut_curie

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Curie